LOGIN  |  REGISTER
Cue Biopharma

List of Medical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 125.37
-0.03 -0.02
1.52M
1.74B
US$ 218.140B
US$ 573.44
-1.80 -0.31
488,916
375.71M
US$ 215.450B
US$ 573.49
4.86 0.85
229,188
354.50M
US$ 203.300B
US$ 226.65
-0.48 -0.21
1.09M
706.35M
US$ 160.090B
US$ 97.76
0.04 0.04
3.44M
1.48B
US$ 144.680B
US$ 365.09
0.73 0.20
426,127
382.42M
US$ 139.620B
US$ 102.36
0.37 0.36
1.92M
1.28B
US$ 131.020B
US$ 811.00
-3.18 -0.39
206,348
123.43M
US$ 100.100B
US$ 714.45
-3.02 -0.42
99,508
79.85M
US$ 57.050B
US$ 195.06
1.30 0.67
642,490
285.42M
US$ 55.670B
US$ 86.97
1.19 1.39
1.58M
580.30M
US$ 50.470B
US$ 198.86
-0.33 -0.17
479,360
237.60M
US$ 47.250B
US$ 145.78
-2.54 -1.71
708,422
283.05M
US$ 41.260B
US$ 81.15
2.16 2.73
909,152
491.20M
US$ 39.860B
US$ 224.74
-0.18 -0.08
625,003
170.30M
US$ 38.270B
US$ 257.79
6.28 2.50
322,449
145.97M
US$ 37.630B
US$ 243.81
1.75 0.72
573,319
138.01M
US$ 33.650B
US$ 1.00
-8.05 -0.57
26,865
20.43M
US$ 28.900B
US$ 66.21
0.96 1.47
1.42M
390.02M
US$ 25.820B
US$ 262.64
1.62 0.62
170,079
98.15M
US$ 25.780B
US$ 396.23
-0.14 -0.04
155,994
59.53M
US$ 23.590B
US$ 305.34
-10.58 -3.35
124,972
70.35M
US$ 21.480B
US$ 259.12
-2.37 -0.91
224,701
82.90M
US$ 21.480B
US$ 182.90
-1.28 -0.69
209,969
111.24M
US$ 20.350B
US$ 279.89
-1.88 -0.67
170,757
71.94M
US$ 20.140B
US$ 128.82
0.78 0.61
183,361
152.80M
US$ 19.680B
US$ 101.19
0.06 0.06
3.32M
189.77M
US$ 19.200B
US$ 93.66
0.50 0.54
936,813
198.18M
US$ 18.560B
US$ 74.98
0.12 0.16
434,271
222.91M
US$ 16.710B
US$ 83.59
6.56 8.52
7.22M
198.81M
US$ 16.620B
US$ 546.85
2.08 0.38
69,016
28.17M
US$ 15.400B
US$ 33.65
0.92 2.81
395,722
423.90M
US$ 14.260B
US$ 186.07
0.30 0.16
501,731
76.36M
US$ 14.210B
US$ 103.75
-4.77 -4.40
1.45M
129.87M
US$ 13.470B
US$ 77.74
1.41 1.85
2.03M
172.86M
US$ 13.440B
US$ 301.95
7.23 2.45
237,057
39.16M
US$ 11.820B
US$ 101.64
-0.91 -0.89
202,210
113.38M
US$ 11.520B
US$ 47.08
0.00 0.00
317,245
216.84M
US$ 10.210B
US$ 90.58
1.84 2.07
379,907
111.41M
US$ 10.090B
US$ 18.65
0.17 0.92
3.95M
514.06M
US$ 9.590B
US$ 165.22
-0.54 -0.33
99,595
56.29M
US$ 9.300B
US$ 184.50
0.46 0.25
274,567
49.22M
US$ 9.080B
US$ 142.88
0.62 0.44
240,862
53.71M
US$ 7.670B
US$ 47.71
-0.67 -1.38
693,671
151.94M
US$ 7.250B
US$ 319.22
-0.84 -0.26
31,140
21.91M
US$ 6.990B
US$ 110.02
1.17 1.07
134,299
57.43M
US$ 6.320B
US$ 79.04
-2.04 -2.52
139,791
77.15M
US$ 6.100B
US$ 17.14
0.33 1.96
130,061
354.19M
US$ 6.070B
US$ 179.66
-1.69 -0.93
70,553
32.22M
US$ 5.790B
US$ 120.00
1.14 0.96
133,854
44.19M
US$ 5.300B
US$ 83.63
-0.46 -0.55
95,192
59.29M
US$ 4.960B
US$ 138.14
-0.49 -0.35
167,540
34.17M
US$ 4.720B
US$ 16.55
-0.01 -0.06
2.14M
284.09M
US$ 4.700B
US$ 79.97
0.00 0.00
0
58.56M
US$ 4.680B
US$ 63.71
1.84 2.97
368,918
66.31M
US$ 4.220B
US$ 140.05
0.01 0.01
338,917
29.06M
US$ 4.070B
US$ 84.81
1.00 1.19
238,185
46.81M
US$ 3.970B
US$ 100.89
-3.82 -3.65
208,530
38.98M
US$ 3.930B
US$ 70.98
0.00 0.00
0
51.11M
US$ 3.630B
US$ 64.14
0.20 0.31
134,078
54.61M
US$ 3.500B
US$ 141.01
-1.34 -0.94
44,889
24.69M
US$ 3.480B
US$ 21.42
0.13 0.61
369,566
148.55M
US$ 3.180B
US$ 61.64
1.58 2.63
233,083
48.08M
US$ 2.960B
US$ 70.07
-0.55 -0.78
128,008
35.04M
US$ 2.460B
US$ 38.11
2.68 7.56
1.33M
55.88M
US$ 2.130B
US$ 44.87
-0.54 -1.19
88,937
47.37M
US$ 2.130B
US$ 70.37
-0.34 -0.48
259,937
29.06M
US$ 2.040B
US$ 41.02
1.77 4.51
291,956
49.72M
US$ 2.040B
US$ 19.09
0.67 3.64
1.49M
105.73M
US$ 2.020B
US$ 32.40
-0.41 -1.25
259,307
61.15M
US$ 1.980B
US$ 84.07
-1.75 -2.04
31,817
22.69M
US$ 1.910B
US$ 27.70
-0.12 -0.43
145,344
67.93M
US$ 1.880B
US$ 35.13
0.02 0.06
149,997
45.86M
US$ 1.610B
US$ 33.73
0.88 2.68
328,252
46.12M
US$ 1.560B
US$ 11.92
-0.25 -2.05
180,791
129.39M
US$ 1.540B
US$ 20.92
0.21 1.01
508,400
67.80M
US$ 1.420B
US$ 11.89
0.12 1.02
691,778
111.98M
US$ 1.330B
US$ 6.00
0.07 1.18
269,507
217.30M
US$ 1.300B
US$ 25.85
-0.75 -2.82
244,409
49.37M
US$ 1.280B
US$ 9.33
-0.06 -0.64
129,727
135.42M
US$ 1.260B
US$ 25.67
-0.16 -0.62
68,810
48.15M
US$ 1.240B
US$ 39.09
-5.15 -11.64
595,237
30.97M
US$ 1.210B
US$ 93.82
-0.11 -0.12
14,033
12.72M
US$ 1.190B
US$ 38.69
-0.93 -2.35
196,159
29.19M
US$ 1.130B
US$ 22.44
-0.49 -2.14
92,588
49.71M
US$ 1.120B
US$ 13.09
0.00 0.00
0
83.72M
US$ 1.100B
US$ 13.35
-0.23 -1.69
121,829
77.89M
US$ 1.040B
US$ 1.35
0.00 0.00
1.05M
767.70M
US$ 1.040B
US$ 6.87
0.01 0.15
141,703
148.10M
US$ 1.020B
US$ 18.69
-0.72 -3.71
291,438
51.43M
US$ 961.230M
US$ 14.45
0.11 0.77
282,524
63.21M
US$ 913.380M
US$ 13.47
0.20 1.51
19,150
67.77M
US$ 912.520M
US$ 27.94
-0.37 -1.31
39,757
30.91M
US$ 863.630M
US$ 19.55
0.31 1.61
140,775
43.39M
US$ 848.270M
US$ 13.80
1.25 9.96
10,481
55.90M
US$ 771.420M
US$ 2.37
-0.16 -6.15
4.64M
301.91M
US$ 714.020M
US$ 19.67
0.52 2.72
337,922
35.82M
US$ 704.580M
US$ 3.07
0.005 0.16
1.23M
226.18M
US$ 693.240M
US$ 7.18
-0.15 -2.05
137,136
93.21M
US$ 669.250M
US$ 5.01
-0.19 -3.65
566,308
127.86M
US$ 640.580M
US$ 15.98
0.08 0.50
33,857
39.60M
US$ 632.810M
US$ 27.86
1.05 3.92
137,590
22.34M
US$ 622.280M
US$ 42.98
0.00 0.00
0
14.30M
US$ 614.610M
US$ 5.85
0.17 2.99
1.64M
96.02M
US$ 561.720M
US$ 1.46
0.02 1.39
396,252
384.57M
US$ 561.470M
US$ 13.56
-0.06 -0.44
61,408
41.20M
US$ 558.470M
US$ 16.65
-0.32 -1.89
32,813
33.31M
US$ 554.610M
US$ 18.99
0.00 0.00
0
28.21M
US$ 535.710M
US$ 12.89
0.40 3.20
247,896
41.12M
US$ 530.040M
US$ 11.16
0.03 0.27
132,556
46.42M
US$ 518.050M
US$ 11.61
0.05 0.43
55,134
41.69M
US$ 483.810M
US$ 7.22
-0.40 -5.25
133,124
66.98M
US$ 483.600M
US$ 15.19
0.07 0.46
3,717
31.66M
US$ 480.920M
US$ 18.52
0.35 1.93
30,503
25.08M
US$ 464.480M
US$ 8.12
-0.22 -2.64
19,218
52.87M
US$ 429.360M
US$ 13.93
0.27 1.98
137,241
27.58M
US$ 384.050M
C$ 1.29
0.02 1.57
14,292
289.14M
C$ 372.990M
US$ 16.06
-0.27 -1.65
44,236
22.66M
US$ 363.810M
US$ 7.77
0.07 0.91
201,684
46.71M
US$ 362.940M
US$ 7.20
0.50 7.46
49,040
49.96M
US$ 359.460M
US$ 9.90
-0.12 -1.20
83,570
35.31M
US$ 349.390M
C$ 2.24
0.00 0.00
0
154.17M
C$ 345.340M
US$ 17.22
0.09 0.53
1,389
19.56M
US$ 336.820M
US$ 19.22
-1.11 -5.46
201,870
15.16M
US$ 291.300M
US$ 1.44
-0.04 -2.38
2.85M
195.55M
US$ 280.610M
US$ 6.67
-0.07 -1.04
139,138
40.86M
US$ 272.330M
US$ 5.69
0.01 0.18
29,175
46.32M
US$ 263.560M
US$ 6.78
0.01 0.15
21,168
38.02M
US$ 257.780M
US$ 6.00
0.00 0.00
0
40.63M
US$ 243.780M
US$ 9.28
-0.07 -0.75
68,731
26.21M
US$ 243.100M
US$ 3.71
-0.13 -3.26
715,719
65.38M
US$ 242.230M
US$ 28.00
0.00 0.00
0
8.53M
US$ 238.840M
US$ 28.14
0.34 1.22
9,871
8.34M
US$ 234.690M
US$ 6.45
-0.20 -3.01
137,153
36.19M
US$ 233.430M
US$ 2.40
-0.04 -1.44
68,977
93.32M
US$ 223.500M
US$ 5.84
0.00 0.00
0
37.47M
US$ 218.820M
US$ 13.99
-1.01 -6.73
88,019
15.25M
US$ 213.350M
US$ 4.84
0.03 0.52
21,180
43.03M
US$ 208.050M
US$ 6.66
-0.09 -1.33
19,690
30.19M
US$ 200.910M
US$ 2.56
0.02 0.63
980,834
77.35M
US$ 197.710M
US$ 22.00
0.20 0.92
15,078
8.94M
US$ 196.680M
US$ 4.63
0.09 1.98
34,746
41.20M
US$ 190.760M
US$ 6.95
-0.04 -0.57
42,706
27.15M
US$ 188.560M
US$ 20.22
-0.34 -1.65
21,634
9.03M
US$ 182.540M
US$ 8.95
-0.01 -0.11
56,806
20.34M
US$ 182.040M
US$ 56.52
0.53 0.95
7,532
3.20M
US$ 180.860M
US$ 3.60
-0.04 -1.10
36,706
49.50M
US$ 178.200M
US$ 2.48
-0.09 -3.50
142,678
71.73M
US$ 177.890M
US$ 2.37
-0.04 -1.46
712,231
74.34M
US$ 175.810M
US$ 2.71
-0.03 -1.09
199,695
63.72M
US$ 172.680M
US$ 7.37
-0.12 -1.60
61,951
22.66M
US$ 166.890M
US$ 4.02
-0.01 -0.30
23,572
41.01M
US$ 164.780M
US$ 4.13
0.10 2.36
33,456
39.82M
US$ 164.260M
US$ 2.40
-0.07 -2.64
2.79M
67.16M
US$ 160.850M
US$ 1.49
-0.09 -5.44
17.76M
106.67M
US$ 159.360M
US$ 11.48
0.09 0.79
30,974
11.94M
US$ 137.070M
US$ 1.04
-0.04 -3.27
728,214
131.10M
US$ 135.690M
US$ 40.98
0.28 0.69
2,725
3.26M
US$ 133.590M
US$ 1.01
-0.01 -0.98
1.49M
113.34M
US$ 114.470M
US$ 2.99
0.01 0.34
6,273
37.63M
US$ 112.510M
US$ 3.53
-0.02 -0.56
64,483
30.49M
US$ 107.630M
US$ 2.46
-0.02 -0.61
19,312
43.44M
US$ 106.650M
US$ 10.50
0.50 5.00
1,831
10.07M
US$ 105.740M
US$ 1.42
0.005 0.35
44,917
72.95M
US$ 103.220M
US$ 1.40
-0.05 -3.45
630,873
68.49M
US$ 95.890M
C$ 0.74
0.00 0.00
500
125.75M
C$ 93.060M
US$ 14.53
-0.03 -0.21
8,326
6.17M
US$ 89.650M
US$ 1.09
0.10 9.99
714,254
82.11M
US$ 89.500M
US$ 2.33
-0.08 -3.12
3,791
37.39M
US$ 86.930M
US$ 2.61
-0.10 -3.69
15,019
33.03M
US$ 86.210M
US$ 0.62
0.0047 0.77
75,176
140.00M
US$ 86.100M
US$ 2.04
-0.12 -5.56
1.02M
41.25M
US$ 84.150M
US$ 4.63
-0.10 -2.01
1.15M
18.15M
US$ 83.940M
C$ 0.68
0.04 6.25
62,300
121.18M
C$ 82.400M
US$ 11.86
-0.20 -1.66
3,629
6.77M
US$ 80.260M
US$ 1.86
-0.06 -2.97
23,893
42.37M
US$ 78.940M
US$ 2.49
-0.18 -6.58
218,011
28.23M
US$ 70.150M
US$ 3.54
0.00 0.00
0
18.60M
US$ 65.840M
US$ 1.29
0.00 0.00
0
49.95M
US$ 64.440M
US$ 3.89
-0.15 -3.60
66,626
16.43M
US$ 63.830M
US$ 8.00
-0.54 -6.32
50,629
7.96M
US$ 63.680M
US$ 5.74
-0.05 -0.86
18,504
10.63M
US$ 61.050M
US$ 1.70
0.01 0.59
235,289
30.69M
US$ 52.170M
US$ 1.15
0.01 0.96
98,652
44.53M
US$ 51.250M
US$ 0.88
-0.02 -2.69
958,314
58.48M
US$ 51.230M
US$ 20.01
0.00 0.00
0
2.54M
US$ 50.830M
C$ 0.46
-0.02 -4.17
6,500
105.09M
C$ 48.340M
US$ 0.69
0.02 2.22
2.93M
68.96M
US$ 47.860M
US$ 0.73
-0.007 -0.95
40,043
62.80M
US$ 45.970M
US$ 24.61
0.00 0.00
0
1.75M
US$ 43.070M
C$ 0.16
0.00 0.00
30,000
257.06M
C$ 39.840M
US$ 4.91
-0.04 -0.81
3,819
8.00M
US$ 39.280M
US$ 1.02
0.00 0.00
654,647
38.44M
US$ 39.210M
US$ 0.31
-0.0004 -0.13
1.43M
122.80M
US$ 38.190M
US$ 0.24
0.0029 1.24
75,503
156.55M
US$ 36.950M
US$ 1.09
-0.03 -2.68
21,744
33.58M
US$ 36.600M
US$ 1.10
-0.009 -0.81
27,122
32.98M
US$ 36.310M
US$ 0.76
0.04 5.55
639,070
44.58M
US$ 34.010M
US$ 0.68
0.004 0.60
115,605
50.00M
US$ 33.750M
US$ 0.07
0.001 1.37
51,737
454.66M
US$ 33.640M
US$ 2.04
0.00 0.00
0
15.37M
US$ 31.350M
US$ 0.85
-0.03 -3.17
546,209
34.36M
US$ 29.240M
US$ 0.45
-0.001 -0.22
51,370
63.60M
US$ 28.620M
US$ 0.70
0.0076 1.10
239,087
40.35M
US$ 28.240M
US$ 0.36
0.01 2.87
320,735
78.63M
US$ 28.230M
US$ 0.92
-0.11 -10.68
495,618
30.39M
US$ 27.960M
US$ 0.82
0.001 0.12
23,544
29.94M
US$ 24.430M
US$ 0.84
-0.0057 -0.67
26,178
28.79M
US$ 24.180M
US$ 0.70
-0.03 -3.47
602,147
34.44M
US$ 23.940M
US$ 0.38
-0.0075 -1.94
459,383
60.89M
US$ 23.080M
C$ 0.27
0.00 0.00
0
78.05M
C$ 20.680M
C$ 0.31
0.005 1.64
3,000
66.61M
C$ 20.650M
C$ 0.19
0.005 2.78
21,000
111.36M
C$ 20.600M
US$ 1.66
-0.05 -2.92
33,090
12.26M
US$ 20.350M
C$ 0.17
0.00 0.00
3,895
114.82M
C$ 18.950M
US$ 1.00
0.04 4.26
32,971
18.65M
US$ 18.720M
US$ 2.07
-0.08 -3.77
30,963
8.99M
US$ 18.600M
US$ 5.49
0.00 0.00
6,673
3.39M
US$ 18.590M
US$ 0.98
-0.02 -2.21
28,694
18.63M
US$ 18.160M
US$ 3.04
0.04 1.47
145,010
5.89M
US$ 17.930M
US$ 1.70
-0.005 -0.29
65,339
9.68M
US$ 16.410M
US$ 0.31
0.00 0.00
0
52.24M
US$ 16.390M
C$ 0.05
0.00 0.00
0
320.55M
C$ 16.030M
US$ 0.93
0.0006 0.06
16,466
17.19M
US$ 15.990M
US$ 2.67
0.00 0.00
0
5.89M
US$ 15.730M
C$ 0.05
-0.005 -9.09
167,800
301.79M
C$ 15.090M
US$ 2.04
0.00 0.00
0
7.09M
US$ 14.440M
C$ 0.09
0.00 0.00
81,000
166.73M
C$ 14.170M
US$ 0.49
0.04 8.65
558
27.80M
US$ 13.620M
US$ 1.59
-0.04 -2.45
23,121
8.14M
US$ 12.940M
US$ 0.35
-0.007 -1.95
623,841
34.10M
US$ 12.000M
US$ 0.61
0.00 0.00
0
19.72M
US$ 11.960M
US$ 1.10
-0.03 -2.65
39,089
10.82M
US$ 11.900M
US$ 4.45
0.38 9.34
180,092
2.62M
US$ 11.660M
US$ 0.72
0.02 2.14
2.05M
15.70M
US$ 11.230M
US$ 1.24
-0.05 -3.52
72,554
8.01M
US$ 9.890M
US$ 1.61
0.00 0.00
0
5.85M
US$ 9.420M
US$ 0.34
-0.001 -0.29
171,317
27.64M
US$ 9.400M
US$ 4.58
0.00 0.00
0
2.04M
US$ 9.340M
US$ 5.77
0.27 4.91
19,891
1.50M
US$ 8.650M
US$ 1.46
-0.001 -0.07
8,439
5.68M
US$ 8.290M
US$ 2.67
0.03 1.14
22,938
3.07M
US$ 8.200M
C$ 0.04
0.00 0.00
11,859
227.04M
C$ 7.950M
US$ 1.71
-0.01 -0.58
29,156
4.50M
US$ 7.700M
US$ 0.37
-0.02 -4.98
726,779
20.22M
US$ 7.480M
US$ 5.62
0.00 0.00
0
1.29M
US$ 7.250M
US$ 8.85
5.74 184.57
17,025
799,966
US$ 7.080M
US$ 0.74
-0.0049 -0.66
35,049
9.45M
US$ 7.010M
US$ 2.33
0.03 1.30
3,846
2.95M
US$ 6.870M
US$ 1.19
0.02 1.71
45,587
5.41M
US$ 6.440M
C$ 0.07
0.00 0.00
0
96.48M
C$ 6.270M
US$ 0.85
-0.02 -2.76
50,022
6.89M
US$ 5.830M
US$ 2.39
0.00 0.00
0
2.39M
US$ 5.710M
C$ 0.05
0.00 0.00
0
101.29M
C$ 5.060M
US$ 5.20
-0.10 -1.89
1.03M
960,012
US$ 4.990M
US$ 0.47
-0.01 -3.07
29,727
9.77M
US$ 4.600M
US$ 4.15
0.06 1.47
19,469
1.09M
US$ 4.520M
C$ 0.05
0.00 0.00
0
100.43M
C$ 4.520M
US$ 0.06
0.00 0.00
0
73.90M
US$ 4.510M
US$ 0.04
-0.0006 -1.35
10,000
97.85M
US$ 4.310M
US$ 2.42
0.00 0.00
22,350
1.67M
US$ 4.040M
US$ 0.35
0.00 0.00
0
11.28M
US$ 3.950M
US$ 0.78
0.00 0.00
0
4.85M
US$ 3.780M
US$ 1.90
-0.04 -2.06
5,344
1.86M
US$ 3.530M
US$ 1.99
-0.05 -2.45
4,908
1.70M
US$ 3.380M
US$ 1.83
0.06 3.11
24,971
1.80M
US$ 3.280M
C$ 0.05
0.00 0.00
108,000
58.00M
C$ 2.900M
US$ 3.67
-0.36 -8.93
155,846
761,318
US$ 2.790M
US$ 0.15
0.00 0.00
0
16.88M
US$ 2.530M
US$ 2.51
-0.12 -4.56
12,461
902,665
US$ 2.270M
US$ 1.21
0.02 1.26
22,499
1.81M
US$ 2.180M
C$ 0.07
0.00 0.00
0
22.82M
C$ 1.600M
US$ 0.47
0.00 0.00
0
3.20M
US$ 1.520M
US$ 0.08
0.00 0.00
0
16.67M
US$ 1.370M
US$ 0.20
0.00 0.00
0
5.24M
US$ 1.060M
US$ 0.03
0.00 0.00
0
25.29M
US$ 860K
US$ 0.04
0.00 0.00
0
16.05M
US$ 642K
US$ 0.01
0.00 0.00
0
28.05M
US$ 337K
C$ 0.005
0.00 0.00
0
59.81M
C$ 299K
US$ 0.26
0.00 0.00
0
427,401
US$ 111K
US$ 0.001
0.00 0.00
0
29.91M
US$ 30K
US$ 0.01
0.00 0.00
0
1.78M
US$ 21K
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 1.60
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
C$ 0.51
0.00 0.00
502
-
C$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest News From Medical Stocks


Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting

Joint study conducted with Memorial Sloan Kettering Cancer Center demonstrates clear, positive impacts on patient care NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be presenting at ASH the findings of a joint study conducted with scientific collaborators from Memorial Sloan Kettering in New York, evaluating Precipio’s BCR::ABL1 assay. The data from a comprehensive study includes... Read more


Owlet Launches TGA-Approved Dream Sock™ in Australia & New Zealand, Expanding International Footprint and Bringing Trusted Pediatric Health Monitoring to More Families Worldwide

TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription marks first international expansion of the Company’s recurring-revenue platform. SYDNEY / Dec 05, 2025 / Business Wire / Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announces that Dream Sock™ is now available for families across Australia and New Zealand. Dream Sock recently... Read more


IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

Cryogenic flow control enhances the efficacy and precision of cryoablation procedures Robust IP portfolio becomes increasingly strategic as global interest in IceCure's  platform and next-generation cryoablation technologies grows following ProSense®'s recent FDA marketing authorization in low-risk breast cancer CAESAREA, Israel, Dec. 5, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of mi... Read more


Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio...

Presentations highlight advancements in cancer recurrence detection with Guardant Reveal and real-time treatment response monitoring with Guardant360 Liquid PALO ALTO, Calif. / Dec 05, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at the 2025 San Antonio Breast Cancer... Read more


Natera Acquires Foresight Diagnostics

Expands Natera’s lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm1 Cutting-edge IP adds to Natera’s portfolio of >500 issued or pending patents Accelerates Natera’s expansion into lymphoma, where Foresight has developed a strong clinical position AUSTIN, Texas & BOULDER, Colo. / Dec 05, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in... Read more


CooperCompanies Announces Fourth Quarter and Full Year 2025 Results

SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today financial results for its fiscal fourth quarter and full year ended October 31, 2025. Fourth quarter 2025 revenue of $1,065.2 million, up 5%, or up 3% organically. Fiscal year 2025 revenue of $4.1 billion, up 5%, or up 4% organically. Fourth quarter 2025 GAAP diluted earnings per share (EPS) of $0.43, down 27%. Fiscal 2025... Read more


TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025

WESTMINSTER, Colo. / Dec 04, 2025 / Business Wire / TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Monday, December 15, 2025 at 2:00 PM ET featuring Juan C. Camacho, MD (Florida State University), who will join company... Read more


VolitionRx Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis

HENDERSON, Nev., Dec. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay in "DETECSEPS", a real-world evaluation of early detection of sepsis. DETECSEPS Consortium was awarded winner of the "Challenge Prevention" call for proposals launched by the French Health Innovation Agency and operated by the Banque Publique d'Investissement, as part of the... Read more


Tenon Medical Announces Successful Completion of Initial Cases with New SImmetry(R)+ SI Joint Fusion System

Procedures Completed in Various Spine Centers of Excellence Throughout the Country Including Florida, Arizona, Ohio, and Texas  SImmetry+ combines 3D-printed titanium implants, a robust joint decorticator, and a streamlined bone graft delivery system to offer treatment solutions aligned with established fusion principles  Immediate revenue impact opportunity while significantly advancing Tenon's competitive position in redefining SI joint fusion with a mu... Read more


Nuwellis Continues Clinician-Driven Growth in Pediatric Care with a Leading Hospital in the Northeast U.S.

Pediatric nephrology and cardiology teams continue to seek out Aquadex for safe, precise fluid management in complex cases MINNEAPOLIS, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, announced today that a leading Northeastern U.S. children’s hospital has initiated an Aquadex Ultrafiltration Program. Pediatric nephrology and cardiology teams... Read more


Envoy Medical to Host Fireside Chat with CEO Brent Lucas and the First Acclaim(R) Cochlear Implant Patient

Event to Take Place December 11th at 4:30 P.M. ET White Bear Lake, Minnesota--(Newsfile Corp. - December 4, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it will host a fireside chat on Thursday, December 11, 2025, at 4:30 P.M. ET featuring a conversation between CEO Brent Lucas and Craig Eggert, the first patient to receive the Acclaim™ cochlear... Read more


DarioHealth's Data-Driven Digital Health Platform Delivers Significant and Sustainable Improvements in Blood Pressure: Findings Published in JMIR Cardio

Peer-reviewed JMIR Cardio study demonstrates real-world clinical impact of data-driven digital nudges on hypertension outcomes Data-driven engagement translates to lower health risks and downstream cost savings for Dario clients Results highlight Dario's ability to deliver lasting impact and further cement the Company's position as a proven leader in evidence-based digital care    NEW YORK, Dec. 4, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the... Read more


Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research

Offering includes Animal Origin-Free Preps, Transfection-Grade Preps and Target Yield with turnaround time starting at four business days for Express Genes Enables nucleic acids therapeutics research, which can include antisense oligonucleotide therapies, gene therapies and more SOUTH SAN FRANCISCO, Calif. / Dec 04, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade Plasmid DNA... Read more


ENDRA Life Sciences’ TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ANN ARBOR, Mich. / Dec 04, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced new results from its 2025 TAEUS Liver... Read more


Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor of MediTouch’s Groundbreaking BalanceTutor™ Rehabilitation System

SAN RAFAEL, Calif. and TNUVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an agreement with Israel-based MediTouch Inc. (“MediTouch”) to become the exclusive authorized sales agent and distributor of MediTouch’s BalanceTutor™ rehabilitation system in the United... Read more


Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

SEATTLE, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) Congress 2026 taking... Read more


Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience

New 100 mg/dL Target Glucose setting offers more customization and tighter glucose management. Enhanced algorithm helps users remain in Automated Mode to improve the user experience. Most requested new features enable healthcare providers to more effectively modify diabetes therapy to meet needs of people with diabetes. ACTON, Mass. / Dec 04, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump... Read more


Becton Dickinson and ChemoGLO™ Collaborate to Expand Hazardous Drug Contamination Testing for Health Care Facilities and Laboratories

FRANKLIN LAKES, N.J., Dec. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and ChemoGLO™, a specialist in hazardous drug detection and decontamination, today announced a strategic collaboration to advance hazardous drug contamination testing in health care settings to improve the safety of health care workers. This collaboration allows facilities to combine the rapid, point-of-care qualitative... Read more


CooperCompanies Announces New Chair of the Board and Strategic Review

SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that its Board of Directors has appointed Colleen Jay to succeed current Chair Robert Weiss, effective January 2, 2026. Mr. Weiss will remain on the Board and stand for reelection for the upcoming year, marking his final term. The Company also announced a formal strategic review aimed at identifying opportunities to enhance long-term shareholder... Read more


Stryker names Spencer Stiles President and Chief Operating Officer

Dylan Crotty promoted to Group President, Orthopaedics Portage, Michighan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today Spencer Stiles has been appointed President and Chief Operating Officer (COO), effective January 1, 2026. In this role, Stiles will lead the company’s global businesses, strategy, and mergers and acquisitions. “Appointing Spencer President and COO strengthens our ability to sustain... Read more


Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, today announced that the U.S. Food and Drug Administration (the “FDA”) has approved the Biologics License Application (“BLA”) for AVANCE® (acellular nerve allograft-arwx). Avance is an acellular nerve scaffold for the treatment of adult and pediatric... Read more


Medtronic announces FDA clearance of Hugo™ robotic-assisted surgery system for urologic surgical procedures

Hugo RAS system brings choice to the U.S., coupled with the full suite of Medtronic surgical offerings, ultimately creating a connected and integrated operating room today and into the future. GALWAY, Ireland, Dec. 3, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in surgical innovation, today announced the U.S. Food and Drug Administration (FDA) has cleared the Hugo™ robotic-assisted surgery (RAS) system for use in urologic surgical procedures.... Read more


Picard Medical and SynCardia Systems CEO to Present at CSI Focus D-HF 2025 in Frankfurt, Germany

TUCSON, Ariz., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Patrick NJ Schnegelsberg, CEO will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming CSI Focus D-HF (Device Therapies in Heart Failure)... Read more


Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

QUEENSBURY, N.Y. / Dec 03, 2025 / Business Wire / Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective study by leading interventional radiologists and oncologists from Asklepios Hospital Barmbek in Hamburg, Germany. The study, titled “Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose... Read more


LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

Eight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant Epilepsy LONDON / Dec 03, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study,... Read more


Inspira Technologies Announces Strategic Leap in Lab Capabilities – Accelerating Next-Generation Diagnostics and Blood Technology

RA'ANANA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic expansion of its core blood laboratory capabilities, marking a substantial step in the Company’s evolution into a broader cutting edge technologies, positioning it for accelerated future growth. The strategic... Read more


QHSLab Announces Launch of Q-Cog™ to Support Early Detection of Mild Cognitive Impairment and Dementia

Initial pilot of 168 patients aged 65 and older identifies 54% with high-risk cognitive scores; digital platform expands company’s value-based care capabilities.  West Palm Beach, FL, Dec. 03, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a healthcare technology company focused on digital medicine and population health innovation, today announced the introduction of Q-Cog™, a comprehensive, cloud-based cognitive assessment designed... Read more


Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces... Read more


Bionano Genomics: Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), announced today that the clinical lab fee schedule (CLFS) for 2026 posted by Centers for Medicare & Medicaid Services (CMS) indicates an increase of 47%, from $1263.53 to $1853.22, for the payment for the Category I Current Procedural Terminology... Read more


bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

SAN ANTONIO, Texas / Dec 03, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer Gordon Downie, MD, PhD, will present a poster at the American Cancer Society National Lung Cancer Roundtable (NLCRT) showcasing three cases in which CyPath® Lung, a noninvasive sputum-based flow cytometry test, successfully identified... Read more


Natera: New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

Largest real-world dataset of personalized circulating tumor DNA (ctDNA) across lymphoma subtypes showed Signatera was prognostic of outcomes and outperformed imaging in detecting recurrence AUSTIN, Texas / Dec 03, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9,... Read more


Apyx Medical Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South Korea

Initial commercial orders for the Apyx One console in South Korea are expected in Q4 2025 CLEARWATER, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the approval and commercial launch of the Apyx One console and single-use handpieces in South Korea following the recent... Read more


Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program

FDA feedback provides clear framework for Nexalin’s planned U.S. Pilot Study and supports a potential De Novo pathway for the Gen-2 SYNC™ device in Alzheimer’s disease HOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the successful completion of a substantive Q-Submission (“Q-Sub”) meeting... Read more


Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval

Humana and UnitedHealthcare, which granted authorization in November, are the two largest Medicare Advantage providers in the U.S., accounting for 47% of all Medicare Advantage enrollees This latest approval will help enhance timely access to cutting-edge personal exoskeleton solutions for individuals with spinal cord injury Reimbursement coverage is expected to give Lifeward stronger revenue and cash flow dynamics to scale growth MARLBOROUGH, Mass. and YOKNEAM... Read more


Shoulder Innovations Announces Strategic Partnership with INS to Introduce a Robotic Platform for Shoulder Arthroplasty

Partnership will Expand Shoulder Innovations' Disruptive Ecosystem with Advanced Enabling Technology, Complementing Surgeon and Patient Needs in the ASC Management to Participate in a Fireside Chat at the Piper Sandler 37th Annual Healthcare Conference Today at 8:30 a.m. ET GRAND RAPIDS, Mich., Dec. 3, 2025 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the Company) (NYSE: SI), a commercial-stage medical technology company exclusively focused... Read more


Becton Dickinson Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes

Three- and Four-Laser BD FACSDiscover™ A8 Cell Analyzers Expand Accessibility of Spectral, Real-Time Imaging Cell Analysis FRANKLIN LAKES, N.J., Dec. 3, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global commercial release of new configurations of cell analyzers featuring breakthrough spectral and real-time cell imaging technologies, enabling more labs in academia, pharma and... Read more


Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update

Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million Fiscal 2025 revenue increased 4.5% to $513.0 million Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million Fiscal 2025 operating loss decreased 64.2% to $30.9 million Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical... Read more


Medtronic begins U.S. commercial launch of the MiniMed™ 780G system with the Instinct sensor, made by Abbott

GALWAY, Ireland, Dec. 2, 2025  /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the broad U.S. commercial launch of the MiniMed™ 780G system integrated with the Instinct sensor, made by Abbott and designed exclusively for MiniMed™ systems. Following U.S. FDA clearance of the system earlier this year to enable integration with the Instinct sensor, the system is now shipping to customers across the U.S., marking a major... Read more


NRC Health Partners with Mosaic Life Care to Advance Patient Experience Across the Midwest

LINCOLN, Neb. & ST. JOSEPH, Mo. / Dec 02, 2025 / Business Wire / Mosaic Life Care, a physician-led health system located in northwest Missouri, announced a new partnership with NRC Health, the leader in healthcare experience management. Together, the organizations will work to elevate patient and employee experience across Mosaic’s system, reinforcing its vision for Mosaic to be the region’s first choice and most trusted partner in healthcare. This commitment to... Read more


SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI

FDA lowers surveillance requirement to 50 patients from 300 patients in original HDE approval based on assessment of first 21 SAVE Surveillance Registry patients  Compelling efficacy data to date along with completion of registry expected to expand QUELIMMUNE market opportunity DENVER, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today the Center for Biologics Evaluation... Read more


Hologic New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration

Findings from 11 investigational studies include new data in premenopausal women and comparative analyses of BCI Testing to the 21-gene assay MARLBOROUGH, Mass. / Dec 02, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced that 11 studies featuring the Breast Cancer Index® (BCI™) Test will be presented at the 2025 San Antonio Breast Cancer Symposium® (SABCS). Findings from these studies support the company’s... Read more


Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory...

Results Support the Further Investigation of the Hemopurifier in Long COVID SAN DIEGO, Dec. 2, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, announced today the 20 November 2025 publication of a pre-clinical study entitled "Increased mannosylation of extracellular vesicles in Long COVID plasma provides a potential therapeutic target for... Read more


Envoy Medical Announces the Grant of Its 40th U.S. Patent

New Patent Adds to Company's Growing Portfolio of Intellectual Property Focused on Fully Implanted Hearing Devices White Bear Lake, Minnesota--(Newsfile Corp. - December 2, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received its 40th active U.S. Patent from the United States Patent and Trademark Office. The new patent further strengthens... Read more


NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting

Data presentations to feature 18-month NAUTILUS results and new Post Approval Study (PAS) analyses on GTC seizure reduction RNS® System to be featured in over 80 scientific presentations and posters, the most of any neuromodulation therapy MOUNTAIN VIEW, Calif. / Dec 02, 2025 / Business Wire / NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its RNS System and NeuroPace AI... Read more


IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform

RESEARCH TRIANGLE PARK, N.C. / Dec 02, 2025 / Business Wire / IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced a strategic collaboration with Amazon Web Services (AWS), naming AWS as IQVIA’s Preferred Agentic Cloud Provider. The partnership, revealed at AWS re:Invent, is a major step in the digital transformation of healthcare and life... Read more


DoctorBox Adds Mainz Biomed’s ColoAlert to Its Portfolio

DNA-based Colorectal Cancer Screening as a Home Test BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), molecular genetics diagnostic company specializing in the early detection of cancer, today announced that its test ColoAlert® has been added to the portfolio of DoctorBox, one of Germany’s leading pioneers in digital health. This marks another important milestone in... Read more


Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium

Signatera Genome demonstrated 100% sensitivity and specificity in detecting breast cancer recurrence in the surveillance setting AUSTIN, Texas / Dec 02, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that at least twelve abstracts highlighting Signatera will be shared at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12. The presentations encompass aggregated... Read more


electroCore: TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen

ROCKAWAY, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced the publication of a peer reviewed paper titled “Non-Invasive Transcutaneous Vagal Nerve Stimulation Enhances Mood, Task Performance, and Learning in a High-Stress Military Training Environment” which will be presented at the Applied Human Factors and Ergonomics (AHFE2025) Conference on December... Read more


Owens & Minor to Present at Upcoming Investor Conferences on December 2, 2025

RICHMOND, Va. / Dec 02, 2025 / Business Wire / Owens & Minor, Inc. (NYSE: OMI) announced today that members of its management team are scheduled to participate in two upcoming investor conferences. Citi 2025 Global Healthcare Conference On Tuesday, December 2, 2025, Ed Pesicka, the Company’s President and Chief Executive Officer, and Will Parrish, the Company’s Vice President of Strategy, Corporate Development, & Investor Relations, are scheduled to participate... Read more


Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference

PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025 at 10:30 a.m ET A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS &... Read more